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1. Introduction 
1.1. Hemoglobin synthesis 
The human hematopoiesis initiates in the second to third embryonic weeks with formation 
of mesoderm-derived blood islands in the extraembryonic mesoderm of the developing 
secondary yolk sac (Migliaccio et al., 1986). Erythropoiesis involves proliferation and 
differentiation of committed erythroid progenitors to mature red blood cells (erythrocytes). 
Although globins represents <0.1% of proteins at the proerythroblast level, it reaches 95% of 
all proteins at the level of reticulocytes (Nienhuis & Benz, 1977). Physiologically, the 
expression of the globin genes is generally regulated in such a way that at any point in 
development the output of the beta ()-globin-like chains equals the alpha (Ǐ)-globin chains 
(Lodish & Jacobsen, 1972). The Ǐ-globin gene cluster contains three genes and several 
pseudogenes arranged from the telomere toward the centromere in the following order: 5'-
ξ2-ξ1-Ǐ2-Ǐ1-Ǐ2-Ǐ1-1-3' (Higgs et al., 1998). The human -globin locus consists of five 
functional -like globin genes, that are arranged in the order of their expression during 
development (5’--G-G---3’), and an upstream regulatory element, the locus control 
region (LCR), that is physically composed of five DNase I-hypersensitive sites (HSs) 
(Grosveld et al., 1987). The most widely studied changes during red cell ontogeny are the 
shifts or “switches” in globin types. Embryonic erythroblasts are characterized by the 
synthesis of the unique hemoglobins Gower I (ǔ2Ǔ2), Gower II (Ǐ2Ǔ2), and Hb Portland (ǔ2Ǒ2). 
The zeta (ǔ)- and epsilon (Ǔ)-globin chains are embryonic Ǐ-like and ǐ-like chains, 
respectively. Thus, a switch from ǔ- to Ǐ- and Ǔ- to gamma (Ǒ)-globin gene production begins 
during the embryonic phase of erythropoiesis but is not complete until fetal erythropoiesis 
is well established. During the transition from yolk sac to fetal liver erythropoiesis (5–8 
weeks), erythroid precursors within the fetal liver co-express embryonic (ǔ- or Ǔ-) and fetal 
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(Ǐ- or Ǒ-) globins both in vivo and in vitro (Peschle et al., 1984). The predominant type of 
hemoglobin synthesized during fetal liver erythropoiesis is fetal hemoglobin (HbF, Ǐ2Ǒ2). 
HbF is formed by Ǒ-globin chain A or G according to the amino acid at the 136 position in 
the Ǒ chain, i.e., alanine or glycine. The proportion of GǑ to AǑ is constant throughout fetal 
development: about 75% of GǑ and 25% of AǑ. However, in adult red cells, the small amount 
of HbF is composed mainly of AǑ (60% vs. 40% of GǑ) (Jensen et al., 1982). Ǐ- and ǐ-globin 
chains combine as a tetramer of two Ǐ- and two ǐ-globin polypeptides along with a heme 
moiety to form the adult hemoglobin molecule (HbA, Ǐ2ǐ2). HbA, detectable at the earliest 
stages of fetal liver erythropoiesis, is also synthesized as a minor component throughout this 
period, but HbA2 (Ǐ2ǒ2), minor hemoglobin in the adult, is undetectable in these early 
stages. From about the 30th gestational week onward, ǐ-globin synthesis steadily increases, 
so that by term 50%–55% of hemoglobin synthesized is HbA. By 4-5 weeks of postnatal age, 
75% of the hemoglobin is HbA, this percentage increasing to 95% by 4 months as the fetal-
to-adult hemoglobin switch is completed. HbF levels in circulating red cells are in a plateau 
for the first 2–3 weeks (as a result of the decline in total erythropoiesis that follows birth), 
but HbF gradually declines and normal levels (<1%) are achieved by 200 days after birth.  
1.2 The GATA-1/2 and Krüppel-like factors role in hemoglobin switching 
The regulation of globin gene switching is a very complex process requiring the 
coordination of different signaling pathways and molecular reactions. Many transcription 
factors controlling globin gene expression have been identified and characterized. These 
factors form a complex network of protein-protein and protein-DNA interactions with each 
other, globin gene promoters, LCR HSs, and other cis-acting intergenic regions 
(Stamatoyannopoulos, 2005). The GATA family of proteins (GATA1–6) comprises zinc 
finger transcription factors that both activate and repress target genes containing a 
consensus GATA binding motif (Orkin, 1992). Binding sites with this motif are present in 
many positions in the Ǐ- and ǐ-globin loci, as well as many other erythroid-expressed genes. 
The founding member of this family, GATA1, was discovered as a ǐ-globin locus-binding 
protein (Pruzina et al., 1991). GATA1 is essential for erythroid cell maturation in vivo 
(Pevny et al., 1989). In addition, GATA1 homodimerizes and interacts with other 
transcription factors, such as SP-1 and erythroid Krüppel-like factor (EKLF/KLF1), further 
contributing to the complex network of GATA factor interactions (Gregori et al., 1996). 
GATA2 is primarily expressed in primitive erythropoiesis, but later in development GATA1 
expression predominates (Leonard et al., 1993). Downregulation of GATA2 is important for 
progression of erythroid cell differentiation (Persons et al., 1999). The protein Friend of 
GATA1 (FOG) is co-expressed with GATA1 during embryonic development in erythroid 
cells (Tsang et al., 1997). GATA1 binds a region upstream of both the HBG1- and HBG2-
promoter, necessary for HbF silencing, in a FOG1 dependent manner leading to recruitment 
of the suppressive NuRD-complex (Harju-Baker et al., 2008). GATA-1, together with FOG-1, 
functions as an anchor in the formation of chromatin looping, and is required for physical 
interactions between the ǐ LCR and ǐ globin promoter (Vakoc et al., 2005). 
The Krüppel-like factors are a family of C2H2 zinc finger DNA binding proteins that are 
important in controlling developmental programs. KLF1 gene is an erythroid cell-specific 
zinc finger transcription factor, containing a DNA-binding domain located at its C-terminus, 
composed of three ‘Krüppel-like’ C2H2 zinc finger motifs, and a proline-rich transactivation 
domain at its N-terminus (Miller & Bieker, 1993). KLF1 preferentially activates the -globin 
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gene promoter by binding with high affinity to the CACCC element (Bieker & Southwood, 
1995). KLF1 is essential for adult ǐ-globin gene transcription and binds to the ǐLCR and ǐ-
globin promoters, required for direct interactions between the ǐLCR and the ǐ-globin gene 
in humans (Donze et al., 1995, Scheme 1). Patients with hereditary persistence of HbF, with 
elevated levels of HbF, have mutations in the gene encoding erythroid transcription factor 
KLF1 (Borg et al., 2010). Recent findings demonstrate that KLF1, and the co-activator BRG1, 
are designated by short-chain fatty acid derivatives to activate the fetal globin genes. The 
SWI/SNF complex chromatin-modifying core ATPase BRG1 is required for Ǒ-globin 
induction by short-chain fatty acid derivatives, and is actively recruited to the Ǒ-globin 
promoter in the KLF1-dependent manner (Perrine et al., 2009). KLF1-GATA1 fusion proteins 
activated ǒ-, Ǒ-, and ǐ-globin promoters, and significantly up-regulated delta (ǒ)- and Ǒ-
globin RNA transcript and protein expression in human erythroleukemic cells (Zhu et al., 
2011). DRED (direct repeat erythroid-definitive) was identified as a repressor of the -globin 
gene, it appears to prevent binding of KLF1 to the -globin gene promoter and silences -
globin expression during definitive erythropoiesis (Tanimoto et al., 2000). KLF2 also 
regulates the expression of the human embryonic Ǔ-globin gene but not the adult ǐ-globin 
gene (Basu et al., 2005). Another erythroid-specific transcription factor, called fetal Krüppel-
like factor (KLF11), activates - and -globin genes in human erythroleukemic cells (Asano et 
al., 1999, Scheme 1). KLF11 also activates -globin transcription via the CACCC element in 
the promoter (Asano et al., 2000). The protein encoded by this gene is a zinc finger 
transcription factor that binds to SP1-like sequences in - and -globin gene promoters.  
 
Sheme 1. Overview of globin genes control by examined transcription factors. 
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1.3 Other factors that participate in hemoglobin switching 
A nuclear protein, special AT-rich binding protein 1 (SATB1), regulates genes through 
targeting chromatin remodeling and its overexpression increases -globin and decreases -
globin gene expression (Wen et al., 2005, Scheme 1). Global changes to chromatin, including 
acetylation, phosphorylation, and methylation play roles in LCR activation. Histone 
acetylation occurs during chromatin remodeling and hyperacetylation is associated with 
transcriptional activation of a locus (Pazin & Kadonaga, 1997). Similar to acetylation, 
phosphorylation of histone H3 disrupts DNA-nucleosome interaction and increases 
transcription factor accessibility to DNA. SATB1 overexpression increased Ǔ-globin and 
decreased Ǒ-globin gene expression accompanied by histone hyperacetylation and 
hypomethylation in chromatin from the Ǔ-globin promoter and HS2, and histone 
hypoacetylation and hypermethylation associated with the Ǒ-globin promoter (Wen et al., 
2005). Mitogen activated protein kinase (MAPK) pathways, as well as the stress activated 
p38 pathway, activate histone H3 phosphorylation (Cheung et al., 2000). Studies on p38 
knockout mice established a role for the p38 stress pathway in the switch from primitive to 
definitive erythropoiesis (Tamura et al., 2000). Mutations in the transcription factor alpha 
thalassemia/mental retardation syndrome X-linked (ATRX), nearly always downregulate Ǐ-
globin expression, provide potentially important insight into the trans-regulation of globin 
gene expression (Gibbons et al., 1995). Alpha hemoglobin stabilizing protein (AHSP) is an 
erythroid-specific protein that forms a stable complex with free alpha-hemoglobin (Kihm et 
al., 2002). It has been found that AHSP expression was highly dependent on the larger 
subunit of nuclear factor erythroid-derived 2 (NFE2) (Guo-wei et al., 2010). The transcription 
factor NFE2 activation of globin production was stimulated by cAMP-dependent protein 
kinase (PKA) in erythroid cells (Casteel et al., 1998).  
BCL11A gene (encoding the transcription factor B-cell lymphoma/leukemia 11A) maintains 
silencing of Ǒ-globin expression in adult erythroid cells and functions as a direct 
transcriptional regulator of the fetal to adult hemoglobin switch in humans. BCL11A protein 
levels vary in erythroid progenitors over the course of human ontogeny. BCL11A is 
expressed as short variant proteins in primitive erythroid progenitors that largely express Ǒ-
globin and as full-length forms at the adult stage with silenced Ǒ-globin genes (Sankaran et 
al., 2008). In erythroid progenitors, BCL11A physically interacts with the NuRD chromatin 
remodelling complex, and the erythroid transcription factors, GATA1 and FOG1. In 
addition, KLF1, as a key activator of BCL11A, controls globin gene switching by directly 
activating ǐ-globin and indirectly repressing Ǒ-globin gene expression (Zhou et al., 2010). 
BCL11A binds the upstream LCR, Ǔ-globin, and the intergenic regions between Ǒ-globin and 
ǒ-globin genes. BCL11A and SOX6 co-occupy the human ǐ-globin cluster along with 
GATA1, and cooperate in silencing Ǒ-globin transcription in adult human erythroid 
progenitors (Xu et al., 2010, Scheme 1). SOX6 has also been suggested to enhance definitive 
erythropoiesis in mouse by stimulating erythroid cell survival, proliferation and terminal 
maturation (Dumitriu et al., 2006). A broad genome expression profile studies led to the 
identification of common genetic polymorphisms in the locus of the ǐ-globin gene, a region 
between the HBS1-like gene HBS1L and the oncogene MYB, as well as within the gene 
BCL11A (Galarneau et al., 2010). HBS1L-MYB intergenic polymorphism on chromosome 
6q23 is associated with elevated HbF levels. MYB and HBS1L expression was significantly 
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reduced in erythroid cultures of individuals with high HbF levels, whereas overexpression 
of MYB in human erythroleukemic cells inhibited Ǒ-globin expression supporting role of 
MYB in HbF regulation (Jiang et al., 2006). The human erythroid precursor cells from 
individuals with higher HbF and higher F cell levels have lower MYB expression associated 
with lower erythrocyte count but higher erythrocyte volume (Jiang et al., 2006). 
MicroRNAs (miRNAs or miRs) are small, 19 to 25 nucleotide long, non-coding RNAs, which 
target mRNAs in a sequence-specific manner, inducing translational repression or decay. 
Increased miRNA-210 levels elevated Ǒ-globin levels in hereditary persistence of HbF 
(Bianchi et al., 2009), while the let-7 family has been associated with hemoglobin switching 
(Noh et al., 2009). Recently, two miRNAs, miR-221 and miR-222, have been identified to 
regulate HbF expression in erythropoietic cells via the kit receptor (Gabbianelli et al., 2010). 
miRNA-150 repression of MYB in hematopoietic progenitor cells, of human bone marrow 
origin, supported MYB's importance in erythroid and megakaryocytic differentiation (Lu et 
al., 2008). It has been reported that miRNA-96, miRNA-146a, let-7a, miR-888 and miR-330a-
3p are significantly more abundant in reticulocytes obtained from adults than from 
umbilical cord blood and therefore are potential inhibitors of Ǒ-globin expression. The miR-
96 has been identified as a direct inhibitor of Ǒ-globin expression (Azzouzi et al., 2011, 
Scheme 1). These findings demonstrate that miRNAs contribute to HbF regulation by the 
post-transcriptional inhibition of Ǒ-globin expression during adult erythropoiesis. 
2. Microarray analysis of globin related genes during ontogenesis 
2.1 Introduction 
Several groups have examined the gene expression profile of human CD34+ hematopoietic 
progenitor cells from bone marrow (BM), peripheral blood (PB) and cord blood (CB) using 
microarray technology (He et al., 2005; Ng et al., 2004; Steidl et al., 2002). The modulation of 
gene expression during ontogeny, in fetal liver (FL)- and CB-derived CD34+CD38  
hematopoietic progenitor cells, appears to overlap broadly with early response genes of 
growth factor stimulated adult (BM) hematopoietic progenitor cells (Oh et al., 2000). Recent 
studies have begun to define a general gene expression profiling for human erythroid cells 
from different origins - adult BM and PB (Goh et al., 2007; Gubin et al., 1999; Fujishima et al., 
2004). In general, it has been hypothesized that globin gene switching may be mediated by 
proteins expressed during different stages of ontogeny.  
Following the same intention, we have performed serial gene expression profiling in human 
differentiating erythroid cells by oligonucleotide microarrays. The several expressed genes 
(GATA1, ALAS2, EPOR, globins, etc.) linked to known erythroid differentiation confirms 
the validity of our approach in establishing the appropriate in vitro cell culture conditions. 
To study the mechanism of globin gene switching, we have performed gene expression 
profiling of erythroid progenitor cells derived from hematopoietic tissues during ontogeny, 
using a large Gene Array to gain insight into the associated molecular pathways. Gene 
expression patterns of CD71+ erythroid progenitor cells, differentiated from human FL, CB, 
BM, PB and granulocyte colony-stimulating factor (G-CSF) mobilized PB (mPB), were 
compared to establish the expression patterns of representative genes.  
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2.2 Material and methods 
2.2.1 Liquid erythroid cell cultures  
CD34+ hematopoietic progenitor cells were purified by positive immunomagnetic selection 
using the MACS cell isolation system (Miltenyi Biotec, Auburn, CA). Fresh BM, PB and G-
CSF stimulated mPB CD34+ cells were collected (AllCells LLC, Berkeley, CA) and proceeded 
with selection. CB CD34+ cells (AllCells LLC) and FL CD34+ cells (Cambrex Bio Science, Inc., 
Walkersville, MD) were collected and frozen. For analysis, CD34+ cells were resuspended in 
medium with erythropoietin (EPO), as already described (Cokic et al., 2003). After 6 days of 
EPO treatment, 5x105 cells were washed and incubated for 20 minutes in the presence of the 
monoclonal antibody anti-CD71 Tricolor for cell staining (Beckman-Coulter, Miami, FL). 
Cells were then washed, fixed and acquired on an LSRII flow cytometer (BD Biosciences, 
San Jose, CA). Data were analyzed with Flowjo software (Tree Star, San Carlos, CA). After 6 
days of erythropoietin treatment and incubation at 37°C (5% CO2, 95% humidity), we used 
the RNeasy protocol for isolation of total RNA from erythroid progenitor cells (Qiagen, 
Valencia, CA) according to the manufacturer's instructions. Concentration and integrity of 
total RNA was assessed using an 8453 UV/Visible Spectrophotometer (Hewlett-Packard 
GmbH, Waldbronn, Germany) and Agilent 2100 Bioanalyzer Software (Agilent 
Technologies, Waldbronn, Germany).     
2.2.2 Microarray studies 
In microarray studies, the numbers of total genes overexpressed in erythroid cells of CB, BM 
and PB origin were determined from three independent samples as biological repeats. FL 
and mPB-derived samples were analyzed in independent duplicate samples at day 6 of 
erythroid liquid culture. High quality oligonucleotide glass arrays were produced 
containing a total of 16,659 seventy-mer oligonucleotides (Operon Inc. Valencia, CA). The 
array includes probes for 2121 hypothetical proteins and 18-expressed sequence tags (ESTs) 
and spans approximately 50% of the human genome (Operon Inc.). The arrays were 
produced in house by spotting oligonucleotides on poly-L-lysine coated glass slides by Gene 
Machines robotics (Omnigrid, San Carlos, CA).  
Total human universal RNA (HuURNA) isolated from a collection of adult human tissues to 
represent a broad range of expressed genes from both male and female donors (BD 
Biosciences, Palo Alto, CA) served as a universal reference control in the competitive 
hybridization. Labeled cDNA probes were produced as described (Risinger et al., 2003). 
cDNA was purified by the MinElute column (Qiagen). Binding buffer PB was added to the 
coupled cDNA, and the mixture applied to the MinElute column and centrifuged. After 
discharging the flow-through, washing buffer PE was added to the column, and centrifuged. 
Then the columns were placed into a fresh eppendorf tube and elution buffer added to the 
membrane, incubated and centrifuged and probe collected. The probe was dried in speed-
vac. Finally, 5 l of 2X coupling buffer and 5 l Cy3 and Cy5 dye (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ) were mixed into the control (HuURNA) and experimental 
cDNAs (huES cell-derived) respectively and incubated at room temperature in dark for 90 
minutes. After incubation, the volume was raised to 60 l by DEPC water and then cDNA 
was purified by the MinElute column and eluted with 13 l elution buffer by centrifugation. 
For hybridization, 36 l hybridization mixture was pre-heated at 100C for 2 minutes and 
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cooled for 1 minute. Total volume of probe was added on the array and covered with cover 
slip. Slides are placed in hybridization chamber and 20µl water was added to the slide, and 
incubated overnight at 65oC. Slides were then washed for 2 minutes each in 2X SSC, 1X SSC 
and 0.1X SSC and spin-dried. Microarray slides were scanned in both Cy3 (532nm) and Cy5 
(635nm) channels using Axon GenePix 4000B scanner (Axon Instruments, Inc., Foster City, 
CA) with a 10-micron resolution. Scanned microarray images were exported as TIFF files to 
GenePix Pro 3.0 software for image analysis. The average of the total Cy3 and Cy5 signal 
gave a ratio that was used to normalize the signals. Each microarray experiment was 
globally normalized to make the median value of the log2-ratio equal to zero. The Loess 
normalization process corrects for dye bias, photo multiplier tube voltage imbalance, and 
variations between channels in the amounts of the labeled cDNA probes hybridized. The 
data files representing the differentially expressed genes were then created. For  
advanced data analysis, gpr and jpeg files were imported into microarray database, and 
normalized by software tools provided by NIH Center for Information Technology 
(http://nciarray.nci.nih.gov/). Spots with confidence interval of 99 (≥ 2 fold) with at least 
150-fluorescence intensity for both channel and 30 μm spot size were considered as good 
quality spots for analysis. Paired t test was used in microarray analysis.  
2.3 Results 
2.3.1 Predominantly elevated genes expression in ontogenic tissues 
In the presence of EPO and other cytokines, CD34+ cells were differentiated in vitro into 
erythroid progenitor cells. Besides flow cytometry for analysis of in vitro erythroid 
differentiation, we already reported measurement of hemoglobin content by benzidine 
staining and high-performance liquid chromatography in erythroid progenitor cells during 
their in vitro differentiation in same culture conditions (Cokic et al., 2003, 2008). The 
transferrin receptor (CD71) is present on early erythroid cells but is lost as reticulocytes 
differentiate into mature erythrocytes (Cokic et al., 2003). At day 6 of erythroid cell culture, 
the erythroid progenitor cells were sorted as 100% CD71+, a well-known early marker of 
erythroid differentiation. In microarray studies, the quantities of tissue specific 
overexpressed genes were determined from two to four independent samples (biological 
repeats). During microarray analysis genes are upregulated or downregulated versus 
HuURNA, what we used as a control alongside each sample. We observed largely 
upregulated genes in all tissues (Table 1).  
Besides common highly expressed genes in erythroid progenitor cells: CD71, Rh-associated 
glycoprotein (RHAG), SERPINE1 mRNA binding protein 1 (SERBP1); the highly expressed 
genes in erythroid cells of FL origin are ribonuclease, RNase A family 2 and 3 (RNASE2/3) 
and serpin peptidase inhibitor, clade B (SERPINB1, Table 1). 
The highly expressed genes in erythroid cells of CB origin are hemoglobin gamma A 
(HBG1), NFE2 and eosinophil peroxidase (EPX). The greatly expressed genes in erythroid 
cells of BM origin are latexin (LXN), coproporphyrinogen oxidase (CPOX) and carbonic 
anhydrase II (CA2). The highly expressed genes in erythroid cells of mPB origin are KLF1, 
aminolevulinate, delta-, synthase 2 (ALAS2) and THO complex 2 (THOC2). The genes with 
reduced expressed in erythroid cells of PB origin are proteoglycan 2 (PRG2), Charcot-
Leyden crystal protein (CLC), EPX and v-myb myeloblastosis viral oncogene homolog  
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Gene 
Name 
Description 
Fold induction vs. HuURNA (±SD) 
FL CB BM mPB PB 
HBG1 hemoglobin, gamma A  4.2±0.7 4.5±0.9 4.1±1 4.3±0.2 4.7±0.6 
CLC Charcot-Leyden crystal protein  4.3±0.4 4.3±0.7 4.6±0.6 4.8±0.4 2.9±0.6 
PRG2 proteoglycan 2, bone marrow 5±0.3 4.2±0.9 4.7±0.5 4.1±0.7 2.9±0.4 
RNASE2 ribonuclease, RNase A family, 2  4.3±0.7 3.7±0.9 3.1±0.6 3.5±0.7 1.4±0.8 
HBD hemoglobin, delta  2±1.3 3.5±0.3 4.3±0.4 4.2±0.4 3.2±0.5 
EPX eosinophil peroxidase  4±0.2 3.4±0.8 2.9±0.7 2.6±1.1 0.9±0.5 
SRGN serglycin  4.3±1 2.8±1 4.4±1.3 4.6±0.4 2.1±0.5 
TFRC transferrin receptor (p90, CD71)  3.1±1 3.3±1.2 4.4±0.3 4.3±0.03 3±0.9 
HBE1 hemoglobin, epsilon 1  3±1.2 2.6±1.5 4.4±1.7 4.6±0.01 3.4±1.3 
RHAG Rh-associated glycoprotein  2.7±1.3 3.2±1.2 2.1±0.9 3.1±0.7 2.1±0.5 
MPO myeloperoxidase  3.8±0.2 3.2±0.6 3.4±0.1   
MYB 
v-myb myeloblastosis viral oncogene 
homolog  
3±0.3 3.1±0.7 2.6±0.4 3.5±0.4 1.7±1 
RNASE3 ribonuclease, RNase A family, 3  3.6±1.2 2.7±1.5 2±1 3.1±0.7 0.6±0.2 
LXN latexin 1.5±0.4 1.9±0.7 4.7±1 4.1±0.5 2.7±0.2 
CD36 CD36 molecule (thrombospondin rec)  1.6±1.1 2.6±0.5 4±1 3.2±0.5 2.1±0.8 
CPOX coproporphyrinogen oxidase 2±0.8 2.7±0.6 3.5±0.7 2.9±0.4 1.8±0.6 
CA2 carbonic anhydrase II  0.15 1±0.3 3.3±0.6 1.8±0.2 1.7±0.5 
CYTL1 cytokine-like 1 1.4±0.8 1.7±0.4 2.8±0.4 3.7±0.3 2.4±0.3 
KLF1 Kruppel-like factor 1 (erythroid) 1±0.4 1.7±0.5 2.5±0.9 3.6±0.3 2.3±0.2 
ALAS2 aminolevulinate, delta-, synthase 2 1.5±0.4 1.4±0.3 2.5±0.9 3.5±0.7 2.7±0.3 
CPA3 carboxypeptidase A3 (mast cell)  1 0.9±0.3 1.9±0.7 3.2±0.4 1.2±0.5 
THOC2 THO complex 2 0.6±0.4 0.9±0.5 1.4±0.7 3.1±0.2 1.6±0.5 
GATA1 globin transcription factor 1 0.9 2.1±0.4 2.7±0.6 2.5±0.3 2.3±0.3 
NFE2 nuclear factor (erythroid-derived 2) 1.4±0.4 1.9±0.5 2.6  1.6±0.5 
SERPINB1 serpin peptidase inhibitor, clade B 2.5±0.2 1.8±0.3 1.7±0.4 0.9±0.3 0.7±0.3 
SERBP1 SERPINE1 mRNA binding protein 1  2.1±0.4 2.4±0.5 1.9±0.7 1.9±0.5 1.6±0.6 
Table 1. Largely up-regulated genes vs. HuURNA among different tissues: FL, CB, BM, 
mPB, PB. Bolded black values represent increased genes expression, whereas bolded gray 
values represent decreased genes expression in comparison to other tissues. 
(MYB). Presence of certain gene in the least two samples (66% filtering), in one group of 
tissues, reduced largely the total gene expression in all tissues. Using the range of 
microarray analysis and filtering reduction, the erythroid cells of FL tissue origin expressed 
1772 genes, CB-derived erythroid cells expressed 3846 genes, BM derived erythroid cells 
expressed 1827 genes, mPB derived erythroid cells expressed 4008 genes, and PB derived 
erythroid cells expressed 1320 genes. The observed gene expression is more than doubled in 
CB and mPB tissues in comparison to other tissues.  
2.3.2 A comparison in genes expression of erythroid cells during subsequent stages 
of development 
Using Venn diagrams we compared total gene expression, determined by microarray 
analysis, among all examined ontogenic tissues. By 66% filtering, we analyzed only genes  
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Fig. 1. Venn diagram of genes expression in erythroid progenitor cells between FL and 
other developmental tissues. A: Comparison among FL, CB and BM tissues; B: Comparison 
among FL, CB and mPB tissues; C: Comparison among FL, CB and PB tissues; D: 
Comparison among FL, BM and mPB tissues. 
present in at least two donor samples per tissue. We compared gene expression of FL-
derived erythroid cell with other ontogenic derived tissues in Figure 1. Shared genes 
expression was more prominent between CB and FL/mPB derived erythroid cells, than 
between FL and BM/PB tissues (Figure 1A-C). Moreover, the FL- and CB-derived erythroid 
cells have the more common genes with mPB-derived erythroid cells than with BM and PB 
tissues (Figures 1D, 2C). The genes related to FL tissue shared the similar expression with 
BM- and PB-derived cells (Figure 2A). In addition, the genes expression in mPB-derived 
erythroid cells contains the majority of genes expressed in FL, BM and PB tissues (Figure 2B,  
 
Fig. 2. Venn diagram of genes expression in erythroid progenitor cells among ontogenic 
tissues. A: Comparison among FL, BM and PB tissues; B: Comparison among FL, mPB and 
PB tissues; C: Comparison among CB, BM and mPB tissues. 
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Fig. 3. Venn diagram of genes expression in erythroid progenitor cells between PB and 
other ontogenic tissues. A: Comparison among CB, BM and PB tissues; B: Comparison 
among CB, mPB and PB tissues; C: Comparison among BM, mPB and PB tissues. 
3C), but not in CB tissue (Figures 2C, 3B). Also, mPB-derived erythroid cells shared more 
genes with BM tissue than with PB tissue (Figure 3C). The genes expression in CB-derived 
erythroid cells overwhelmed the gene expression in BM tissues and almost completely in PB 
tissue (Figure 3A). 
Comparison in genes expression between FL- and CB-derived erythroid cells revealed 
couple statistically significant genes (p<0.01, Table 2): POLE3 and BRP44. Negative values in 
Tables represent downregulated genes expression in ontogenic tissues in contrast to 
HuURNA, whereas positive values represent upregulated genes.  
 
Gene Description 
p 
value 
FL 
Mean±SD 
CB 
Mean±SD
Tissue 
presence 
POLE3  polymerase epsilon 3 0.0022 0.4±0.22 0.8±0.4 FL, CB, mPB, PB 
SNRPD3  
small nuclear 
ribonucleoprotein D3 
0.0036 0.8±0.02 1.6±0.4 FL, CB, mPB 
ZFP36  zinc finger protein 36 0.0072 -1.6±0.07 -2.3±0.6 FL, CB, mPB 
BRP44  brain protein 44  0.0063 -0.14±0.09 0.5±0.1 All tissues 
Table 2. Comparison of statistically significant (p<0.01) genes between FL and CB tissues.  
Brain protein 44 (BRP44) gene expressions was highly significantly increased in CB-derived 
erythroid cells vs. FL-derived cells (Table 2), but was reduced in comparison to PB-derived 
cells (Table 8). BRP44 gene was stable expression in all examined ontogenic tissues, whereas 
POLE 3 gene expression was absent in BM tissue (Table 2). Comparison in genes expression 
between FL- and BM-derived erythroid cells exposed more statistically significant genes 
(Table 3): SBNO2, WDR1 and CTAG2 present in all tissues.  
WD repeat domain 1 (WDR1) gene expressions was significantly increased in BM- vs. PB-
derived erythroid cells (Table 10), but was reduced in comparison to FL-derived cells (Table 
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3). Evaluation in genes expression between FL- and mPB-derived erythroid cells exposed 
also statistically significant genes (Table 4): ME2 present just in FL and mPB tissues, highly 
upregulated EEF1B2 expressed in all tissues. IFI30 was downregulated in mPB-derived 
erythroid cells, but was upregulated in FL-derived cells (Table 4). 
 
Gene Description p value
FL 
Mean±SD
BM 
Mean±SD
Tissue 
presence 
SPRR2B small proline-rich protein 2B 0.0001 -0.8±0.03 -0.9±0.5 FL, CB, BM,mPB 
SRI  sorcin  0.0014 0.9±0.04 1.1±0.2 All tissues 
KPNA2 karyopherin alpha 2  0.002 0.5±0.005 1 ±0.2 All tissues 
SDHC  
succinate dehydrogenase 
complex, subunit C 
0.0021 0.1±0.05 0.2±0.2 All tissues 
NCOA4 nuclear receptor coactivator 4 0.0048 2±0.3 1.8±0.4 All tissues 
SBNO2  strawberry notch homolog 2 0.005 -1.5±0.02 -1.1±0.6 All tissues 
TTC3  
tetratricopeptide repeat 
domain 3  
0.0057 0.3±0.08 0.6±0.1 FL, CB, BM,mPB 
PTTG1  
pituitary tumor-
transforming1  
0.0078 0.7±0.05 1±0.2 All tissues 
WDR1  WD repeat domain 1  0.0079 0.5±0.002 0.3±0.1 All tissues 
MINK1  Misshapen-like kinase 1  0.0089 -1.2±0.1 -0.9±0.5 All tissues 
CTAG2  cancer/testis antigen 2  0.0094 -0.1±0.25 -0.2±0.54 All tissues 
Table 3. Comparison of statistically significant (p<0.01) genes between FL and BM tissues. 
 
Gene Description p value
FL 
Mean±SD
mPB 
Mean±SD
Tissue 
presence 
ME2  
malic enzyme 2, NAD(+)-
dependent, mitochondrial  
0.0068 1.19±0.15 0.9±0.14 FL, mPB 
INSIG1 insulin induced gene 1  0.0073 -0.08±0.4 -0.01±0.4 FL, mPB 
EEF1B2 
eukaryotic translation 
elongation factor 1 beta 2  
0.0009 1.77±0.12 2.3±0.12 All tissues 
ZNF224  zinc finger protein 224  0.0015 -0.2±0.06 0.9±0.06 FL, CB, BM, mPB 
CSDE1  
cold shock domain 
containing E1, RNA-binding 
0.004 0.56±0.08 0.6± 0.02 All tissues 
IFI30  
Interferon, gamma-inducible 
protein 30  
0.0059 0.06±0.05 -2±0.07 FL, CB, BM, mPB 
PSMD11 
proteasome 26S, non-
ATPase,11  
0.0091 0.67±0.17 0.18±0.16 All tissues 
PGAM1 phosphoglycerate mutase 1  0.0093 0.87±0.15 0.06±0.16 FL, CB, mPB, PB 
PTPRC 
protein tyrosine phosphatase, 
receptor type, C  
0.0093 1.42±0.75 1.5±0.75 FL, CB, BM, mPB 
Table 4. Comparison of statistically significant (p<0.01) genes between FL and mPB tissues. 
Comparison between FL- and PB-derived erythroid cells revealed just two significant genes: 
TOP1 and CAT (Table 5). TOP1 and CAT genes have higher levels in FL tissue than in PB.  
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Gene Description 
p 
value 
FL 
Mean±SD
PB 
Mean±SD 
Tissue 
presence 
TOP1  topoisomerase I  0.0017 1.3±0.34 0.9±0.7 All tissues 
CAT  catalase  0.0042 1.8±0.18 1.3±0.26 FL, CB, mPB, PB 
Table 5. Comparison of statistically significant (p<0.01) genes between FL and PB tissues. 
Evaluation in genes expression between CB- and BM-derived erythroid cells exposed 
several genes: WAPAL, GRB2, GOLIM4, etc. (Table 6). CTDSP1 has the elevated expression 
in CB tissue, while TPST2 has the higher expression in BM tissue (Table 6).  
 
Gene Description p value 
CB 
Mean±SD
BM 
Mean±SD 
Tissue 
presence 
SCAMP2
  
secretory carrier membrane 
protein 2  
0.0022 0.4±0.22 0.8±0.4 CB, BM, PB 
ABCF2 ATP-binding cassette, sub-family F 0.0075 -0.2±0.17 0.22±0.08 CB, BM, PB 
ZNF16  zinc finger protein 16  0.0093 0.2±0.2 0.6±0.18 CB, BM, PB 
GRIPAP1 GRIP1 associated protein 1  0.0014 -0.6±0.45 -0.06±0.45 All tissues 
WAPAL wings apart-like homolog  0.0023 1.3±0.1 1.7±0.1 All tissues 
TPST2  tyrosylprotein sulfotransferase 2 0.0029 0.8±0.26 1.6±0.21 All tissues 
TPSB2  tryptase beta 2  0.0035 -0.7±0.43 1±0.33 All tissues 
CCNB2 cyclin B2  0.0037 1.3±0.21 1.7±0.19 All tissues 
RPS13  ribosomal protein S13  0.0041 1.9±0.23 1.5±0.21 All tissues 
GRB2  
growth factor receptor-bound 
protein 2  
0.0067 -0.06±0.4 0.4±0.38 All tissues 
GSK3A glycogen synthase kinase 3α 0.0071 -1±0.04 -0.8±0.06 All tissues 
CTDSP1 
carboxy-terminal domain,  A 
polypeptide small phosphatas 1  
0.0077 0.4±0.23 -0.05±0.01 All tissues 
ZNF43  zinc finger protein 43  0.0086 0.9±0.11 1.2±0.09 All tissues 
GOLIM4  golgi integral membrane protein 4 0.0094 0.4±0.04 0.85±0.07 All tissues 
Table 6. Comparison of statistically significant (p<0.01) genes between CB and BM tissues. 
Zinc finger protein 43 (ZNF43) has also significantly increased gene expressions in BM-
derived erythroid cells compared to CB- and PB-derived erythroid cells (Tables 6, 10). Golgi 
integral membrane protein 4 (GOLIM4) gene has also significantly increased expressions in 
BM-derived erythroid cells compared to CB- and mPB-derived erythroid cells (Tables 6, 9). 
Assessment in genes expression between CB- and mPB-derived erythroid cells uncovered 
several genes: ARF4, PHIP, ACIN1, etc. (Table 7). ARF4 has highly upregulated gene 
expression in CB-derived cells compared to mPB tissue.  
Measurement in genes expression profile between CB and PB tissues revealed the 
downregulated genes PPFIA4 and WIPI2, as well as upregulated genes FBL and BRP44 
(Table 8). WIPI2 was less downregulated in PB tissue than in CB tissue. 
Determination of statistical significance between BM and mPB tissues showed the prevalent 
quantity of genes: MYCL2, ADIPOR2 and POP7 present in CB, BM and mPB tissues; 
NFATC3, YY1, GCA present in all tissues except PB; YWHAZ, TACC3, UBE2D3 present in 
BM, mPB and PB tissues (Table 9). 
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Gene Description P value 
CB 
Mean±SD
mPB 
Mean±SD 
Tissue 
presence 
GRN  granulin  0.0007 -1.1±0.35 -1.5±0.16 All tissues 
PHIP  
pleckstrin homology 
domain interacting protein 
0.0009 0.5±0.38 1.4±0.29 All tissues 
ARF4  ADP-ribosylation factor 4  0.0037 0.4±0.3 0.04±0.15 FL, CB, BM, mPB 
UBE2V1 
ubiquitin-conjugating 
enzyme E2 variant 1  
0.0044 0.7±0.06 0.4±0.04 All tissues 
ACIN1 
apoptotic chromatin 
condensation inducer 1  
0.0058 0.6±0.11 0.3±0.05 All tissues 
XRCC6 
X-ray repair complemen-
ting defective repair in 
Chinese hamster cells 6  
0.0067 1.2±0.13 0.8±0.11 All tissues 
F2R  
coagulation factor II 
(thrombin) receptor  
0.0072 -0.2±0.22 -0.9±0.21 FL, CB, BM, mPB 
SNRPA  
small nuclear ribonucleo-
protein polypeptide A  
0.008 1.6±0.37 1.1±0.02 FL, CB, mPB 
LGALS1  
lectin, galactoside-binding, 
soluble, 1  
0.0093 -1.3±0.48 -0.5±0.57 FL, CB, mPB 
Table 7. Comparison of statistically significant (p<0.01) genes between CB and mPB tissues. 
 
Gene Description p value
CB 
Mean±SD 
PB 
Mean±SD 
Tissue 
presence 
PPFIA4  
protein tyrosine phos-
phatase, f polypeptide, 
interacting protein Ǐ 4  
0.0016 -1.3±0.37 -0.06±0.44 All tissues 
WIPI2  
WD repeat domain, 
phosphoinositide 
interacting 2  
0.0043 -0.3±0.08 -0.02±0.14 All tissues 
FBL  fibrillarin 0.0056 1.5±0.29 0.9±0.36 All tissues 
BRP44  brain protein 44  0.0059 0.5±0.13 1±0.14 All tissues 
Table 8. Comparison of statistically significant (p<0.01) genes between CB and PB tissues. 
 
Gene Description p value
BM 
Mean±SD
mPB 
Mean±SD
Tissue 
presence 
MYCL2  
v-myc avian 
myelocytomatosis viral 
oncogene homolog 2  
0.0006 -0.7±0.26 -1.4±0.26 CB, BM, mPB 
SKAP2  
src kinase associated 
phosphoprotein 2  
0.0012 -1.1±0.3 -1.6±0.31 CB, BM, mPB 
MPHOSPH
9  
Mphase phosphoprotein 
mpp9  
0.0012 -0.7±0.18 -1.3±0.19 CB, BM, mPB 
SLC25A39 
solute carrier family 25, 
member 39 
0.0013 1.5±0.13 0.9±0.07 CB, BM, mPB 
www.intechopen.com
 
Hematology – Science and Practice 
 
148 
Gene Description p value
BM 
Mean±SD
mPB 
Mean±SD
Tissue 
presence 
UBE2NL  
ubiquitin-conjugating 
enzyme E2N-like  
0.0015 0.9±0.17 0.6±0.17 CB, BM, mPB 
POP7  
Processing of precursor 7, 
ribonuclease P/MRP subunit 
0.0027 -0.4±0.21 0.28±0.12 CB, BM, mPB 
ANKH  
ankylosis, progressive 
homolog  
0.0031 -0.5±0.22 -1.2±0.21 CB, BM, mPB 
ADIPOR2 adiponectin receptor 2  0.0045 0.6±0.32 0.6±0.01 CB, BM, mPB 
ZBTB43  
zinc finger and BTB domain 
containing 43  
0.0041 -0.9±0.22 -1.4±0.21 CB, BM, mPB 
RBM8A  
RNA binding motif protein 
8A  
0.0048 -0.9±0.45 -0.3±0.13 CB, BM, mPB 
ZYG11B  zyg-11 homolog B  0.0062 -0.2±0.28 -0.9±0.23 CB, BM, mPB 
APBB2  
amyloid beta precursor 
protein-binding, family B, 
member 2  
0.0074 -0.8±0.16 -1.1±0.17 CB, BM, mPB 
CEP97  centrosomal protein 97kDa  0.0082 -0.6±0.09 -1.4±0.1 CB, BM, mPB 
KLRD1  
killer cell lectin-like receptor 
subfamily D 
0.0011 -0.4±0.16 -1.3±0.16 FL, CB, BM, mPB 
TOMM34  
translocase of outer 
mitochondrial membrane 34 
0.0035 -0.5±0.21 -0.6±0.15 FL, CB, BM, mPB 
NFATC3  
nuclear factor of activated T-
cells, cytoplasmic, 
calcineurin-dependent 3  
0.0045 1.3±0.19 0.9±0.23 FL, CB, BM, mPB 
YY1  YY1 transcription factor  0.0047 1.4±0.18 0.8±0.22 FL, CB, BM, mPB 
SSB  Sjogren syndrome antigen B 0.0050 2.7±0.72 2.3±0.003 FL, CB, BM, mPB 
UBC  ubiquitin C  0.0069 -1±0.53 -1.3±0.08 FL, CB, BM, mPB 
UBA1  
ubiquitin-like modifier 
activating enzyme 1  
0.0083 -0.4±0.6 -0.6±0.17 FL, CB, BM, mPB 
LRRC59  
leucine rich repeat 
containing59  
0.0086 1.9±0.25 1.5±0.03 FL, CB, BM, mPB 
GCA  
grancalcin, EF-hand calcium 
binding protein  
0.0098 1.2±0.21 0.4±0.17 FL, CB, BM, mPB 
TACC3  
transforming, acidic coiled-
coil containing protein 3  
0.0011 0.02±0.01 -0.3±0.03 BM, mPB, PB 
LMNB1 lamin B1 0.0014 1±0.1 -0.1±0.04 BM, mPB, PB 
SREBF2  
sterol regulatory element 
binding  
0.0019 -0.6±0.05 -2.1±0.18 BM, mPB, PB 
UBE2D3  
ubiquitin-conjugating 
enzyme E2D 3  
0.0032 1.02±0.06 0.5±0.001 BM, mPB, PB 
YWHAZ  
tyrosine 3-mono 
oxygenase/tryptophan 5-
monooxygenase activation 
protein, zeta polypeptide  
0.0042 1.4±0.08 0.7±0.04 BM, mPB, PB 
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Gene Description p value
BM 
Mean±SD
mPB 
Mean±SD
Tissue 
presence 
GOLIM4  
golgi integral membrane 
protein 4  
0.0044 0.8±0.02 0.29±0.05 BM, mPB, PB 
GLE1  
GLE1 RNA export mediator 
homolog  
0.0049 -0.4±0.02 0.29±0.12 BM, mPB, PB 
CORO1C  
coronin actin binding protein 
1C  
0.0049 1.4±0.1 0.6±0.08 BM, mPB, PB 
ARHGDIB  
Rho GDPdissociation 
inhibitorβ 0.0075 1.4±0.02 1.2±0.03 BM, mPB, PB 
TMEM187  transmembrane protein 187  0.0082 -0.4±0.08 -0.9±0.03 BM, mPB, PB 
TIMM23  
translocase of inner 
mitochon-drial membrane 23 
homolog  
0.0088 0.9±0.1 0.3±0.05 BM, mPB, PB 
PSMB5  proteasome subunit, β type, 5 0.0092 0.3±0.02 0.02±0.02 BM, mPB, PB 
Table 9. Comparison of statistically significant (p<0.01) genes between BM and mPB tissues. 
YY1 transcription factor has significantly increased gene expressions in BM-derived 
erythroid cells compared to PB- and mPB-derived erythroid cells (Tables 9, 10). 
Measurement of statistical significance between BM and PB tissues revealed the following 
significant genes: NUCKS1 and KDM3B prevalent in BM tissue, ATF5 and ATP5L prevalent 
in BM tissue (Table 10).  
 
Gene Description p value
BM 
Mean±SD
PB 
Mean±SD 
Tissue 
presence 
NUCKS1
  
nuclear casein kinase and cyclin-
dependent kinase substrate 1  
 0.0092  1.1±0.62  0.7±0.12   CB, BM,PB  
KDM3B  
lysine (K)-specific demethylase 
3B  
 0.0002  0.8±0.01  0.15±0.03  BM, mPB, PB 
WDR1  WD repeat domain 1   0.0018  0.3±0.1   -0.2±0.03  BM, mPB, PB 
YY1  YY1 transcription factor   0.0018  1.4±0.2   0.25±0.14  BM, mPB, PB 
FEN1  
flap structure-specific 
endonuclease 1  
 0.004  2.7±0.1   1.13±0.2  BM, mPB, PB 
ATF5  activating transcription factor 5   0.0057  -0.8±0.1  -0.2±0.14  BM, mPB, PB 
ZNF43  zinc finger protein 43   0.0058  1.2±0.08  0.5±0.15   BM, mPB, PB 
ATP5L  
ATP synthase, H+ transporting, 
mitochondrial F0 complex, 
subunit G  
 0.0071  0.3±0.08  0.78±0.09  BM, mPB, PB 
HLA-C  
MHC class I human leukocyte 
antigen 
 0.0046  -2.7±0.7  -2.1±0.88 CB,BM,PB  
Table 10. Comparison in statistically significant (p<0.01) gene between BM and PB tissues. 
Flap structure-specific endonuclease 1 (FEN1) gene has significantly decreased expressions 
in PB-derived erythroid cells compared to BM- and mPB-derived erythroid cells (Tables 10, 
11). Similarity in genes expression between mPB and PB tissues was limited on four 
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significant genes: TXNIP, EIF3E, FEN1 and FECH (Table 11). TXNIP was present and 
downregulated just in mPB and PB tissues, whereas EIF3E and FEN1 was highly 
upregulated in all tissues and predominantly in mPB-derived erythroid cells. FECH has 
more prominent expression in PB- than in mPB-derived cells. 
 
Gene Description p value 
mPB 
Mean±SD
PB 
Mean±SD
Tissue 
presence 
TXNIP 
Brain-expressed HHCPA78 
homolog VDUP1 
0.0063 -1.3±0.05 -0.14±0.18 mPB, PB 
EIF3E 
eukaryotic translation 
initiation factor 3, subunit E 
0.0003 2.5±0.14 1.2±0.24 All tissues 
FEN1 
flap structure-specific 
endonuclease 1 
0.0028 2±0.21 1.13±0.21 All tissues 
FECH ferrochelatase  0.0074 1.6±0.7 2.5±0.59 FL, CB, mPB, PB 
Table 11. Comparison in statistically significant (p<0.01) gene between mPB and PB tissues. 
2.3.3 Signaling pathways related to globin genes expression 
It has been already reported that Ǒ globin genes expression is regulated by nitric oxide (NO) 
and p38 MAPK signaling pathways (Cokic et al., 2003; Ramakrishnan & Pace, 2011). We 
examined the genes related to those pathways in erythroid progenitor cells during ontogeny 
in succeeding tissues (Figure 4). Protein kinase, cAMP-dependent, regulatory, type II, beta 
(PRKAR2B) has the highest expression in NO signaling pathways linked genes throughout 
the ontogeny reaching the top in PB-derived erythroid cells. Calmodulin 2 (CALM2) gene 
demonstrates decline in expression during ontogeny, as well as protein phosphatase 3 beta 
isoform (PPP3CB, Figure 4A). Downregulation in gene expression during ontogeny was 
shown for protein kinase, cAMP-dependent, regulatory, type I, alpha (PRKAR1A) and 
calmodulin 3 (CALM3). Regarding p38 MAPK signaling pathway, transforming growth 
factor, beta 1 (TGFB1) gene expression was predominant in FL- and BM-derived erythroid 
cells, while heat shock 27kDa protein 1 (HSPB1) was decreased in BM-derived erythroid 
cells (Figure 4B). Linked to p38 MAPK, v-myc myelocytomatosis viral oncogene homolog 
(MYC) has the most upregulated gene expression throughout the ontogeny (Figure 4B). 
2.3.4 Discussion 
To recognize sets of genes that reveal the essential mechanisms in hematopoiesis, as 
potential novel therapeutic targets, several groups have performed individual gene 
expression profiling in erythroid cells from certain tissues during ontogenesis. We extended 
those studies, of gene expression pattern of ontogenic tissues, to compare gene expression 
from fetal to adult hematopoiesis as a more reflective and comprehensive overview of 
erythropoiesis. Gene expression in normal human erythroid progenitor cells has been 
described and generally static expression analysis was performed on cultured human 
erythroid progenitor CD71+ cells derived from CD34+ cells in the presence of EPO and 
cocktail of cytokines. We presented the number of total genes overexpressed in evaluated 
tissues, the most dominant in CB and mPB tissues. Also, the highly expressed genes are 
SERPINE1, PRG2, CLC, HBG1, NFE2 and EPX. General genes expression was more present 
between CB and FL/mPB derived erythroid cells, than between FL and adult tissues.  
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Fig. 4. Gene expression in signaling pathways related to globins stimulation determined 
by microarray analysis. A: Induction of Nitric oxide signaling pathway related genes in 
erythroid progenitor cells during human ontogeny. B: Induction of p38 MAPK signaling 
pathway related genes in erythroid progenitor cells during human ontogeny. 
Comparison between certain tissues revealed the statistically significant genes: TOP1, CAT, 
IFI30 in FL tissue, ARF4, CTDSP1 in CB tissue, WDR1, ATF5, YWHAZ in BM tissue, EIF3E 
and FEN1 in mPB tissue, FECH in PB tissue. PRKAR2B has the highest expression in NO 
signaling pathways, while MYC has the most upregulated gene expression in p38 MAPK 
signaling pathway in erythroid progenitor cells throughout ontogeny. 
3. Nitric oxide interaction with signaling pathways related to erythropoiesis  
It has been found that proliferation of erythropoietic cells is more related to activation of 
JAK-STAT and MAPK p42/44 signaling pathways, whereas the survival of erythropoietic 
cells correlated better with activation of PI-3K-AKT, JAK-STAT and MAPK p42/44 
pathways (Ratajczak et al., 2001). During erythroid maturation, the p38 MAPK regulates Ǒ-
globin transcription through its downstream effector cAMP response element binding 
protein 1 (CREB1) which binds the GǑ-globin 3’,5’-cyclic adenosine monophosphate (cAMP) 
response element (Ramakrishnan & Pace, 2011). NO is a diffusible free radical that plays a 
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role as a chemical messenger involved in vasodilator, neurotransmitter, and anti-platelet 
aggregation. NO is produced and released from three different isoforms of NO synthase 
(NOS) that convert the l-arginine and molecular oxygen to citrulline and NO in cells: 
endothelial (eNOS), inducible (iNOS), and neuronal (nNOS) (Cokic & Schechter, 2008). NO 
readily diffuses across cell membranes into neighboring cells, or may produce effects distant 
from its site of production transported by vehicles such as low-molecular weight S-
nitrosotiols, S-nitrosylated proteins including hemoglobin and albumin, and nitrosyl-metal 
complexes which liberate NO spontaneously or after cleavage by ectoenzymes (Bogdan, 
2001). A significance of NO in erythroid differentiation has been founded on demonstration 
that NO donors inhibit growth of erythroid primary cells and colony cultures (Maciejewski 
et al., 1995). Besides observation that NO inhibited erythroid differentiation induced by 
butyric acid, antitumour drugs aclarubicin and doxorubicin, but not by hemin (Chénais et 
al., 1999), additional study demonstrated inhibitory effect of NO in the hemin-induced 
erythroid differentiation (Kucukkaya et al., 2006). NO decreased colony-forming unit-
erythrocytes (CFU-E) and CFU-granulocyte macrophage (CFU-GM) formation derived from 
human bone marrow mononuclear cells. Moreover, NO increased CFU-GM and decreased 
CFU-E formation derived from CD34+ hematopoietic progenitor cells (Shami & Weinberg, 
1996). Although NO increased intracellular levels of guanosine 3’,5’-cyclic monophosphate 
(cGMP) in bone marrow cells, addition of a membrane permeable cGMP analogue did not 
reproduce previously mentioned effects of NO in bone marrow derived colonies (Shami & 
Weinberg, 1996). We have previously shown that HbF stimulation is dependent on 
NO/cGMP signaling pathway in erythroid progenitor cells (Cokic et al., 2003). NO-releasing 
agents and cGMP analogues inhibit murine erythroleukemia cell differentiation and 
suppress erythroid-specific gene expression such as beta-globin and delta-aminolevulinate 
synthetase (Suhasini et al., 1995). Serum nitrate and nitrite (NOx) concentrations correlated 
inversely with hemoglobin levels (Choi et al., 2002).  
EPO increased the level of phosphorylated eNOS and stimulated NO production and cGMP 
activity during hypoxia (Beleslin-Cokic et al., 2004; Su et al., 2006). Phospho-eNOS and eNOS 
were significantly induced by hypoxia (Beleslin-Čokić et al., 2011). NO participates in stability 
control of hypoxia inducible factor (HIF)-1Ǐ and induces HIF-1Ǐ accumulation and HIF-1-
DNA binding (Kovacević-Filipović et al., 2007). Hypoxia and EPO increased erythropoietin 
receptor (EPOR) gene expression and protein level (Beleslin-Čokić et al., 2011). The 
physiologically low oxygenation of bone marrow is a regulator of hematopoiesis maintenance, 
and physiological levels of O2 should be considered as an important environmental factor that 
significantly influences cytokine activity (Brüne & Zhou, 2007; Krstic et al., 2009a). The 
proportion of Ǒ–globin mRNA (the Ǒ/(Ǒ+ǐ) mRNA ratio) increased with reduced oxygen, 
reaching a maximum value at 5% O2 of 1.5 to 4-fold higher than at 20% O2, and then decreased 
as the O2 dropped to 2%. In parallel, the proportion of HbF (the HbF/(HbF+HbA) ratio) also 
peaked at 5% O2. Reported increase in the HbF was generally lower than that of the Ǒ-globin 
mRNA, suggesting that although globin mRNA accumulation is primarily under 
transcriptional regulation, additional post-transcriptional processing such as globin chain 
stability contribute to the amount of produced hemoglobins (Rogers et al., 2008). 
4. Nitric oxide influence on hematopoietic microenvironment in bone marrow  
Various growth factors, cytokines, and chemokines are secreted by human hematopoietic 
progenitor cells, myeloblasts, erythroblasts, and megakaryoblasts to regulate normal 
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hematopoiesis in an autocrine/paracrine manner. Furthermore, each stromal cell in the bone 
marrow may provide the preferable microenvironment for a rapid expansion of the lineage-
restricted progenitor cells (Kameoka et al., 1995; Majka et al., 2001). We showed that the 
human endothelial cells and macrophages contain NOS activity, representing the potential 
pool for NO production. The erythroid progenitor cell co-cultures with either macrophages 
or endothelial cells, stimulated by NO-inducers, demonstrated more elevated levels of Ǒ-
globin gene expression than in the erythroid cells only (Čokić et al., 2009). This observation 
suggests that NO could come out of the bone marrow stromal cells and diffuse into the 
erythroid progenitor cells largely participating in Ǒ-globin gene induction, linked to stromal 
cells augmented capability for NO production. This supplemented NO production, in the 
hematopoietic microenvironment, has the potential to enhance HbF synthesis in erythroid 
progenitor cells, which still have low hemoglobin levels and presumably low scavenging 
activity. Accumulating evidence emphasized the involvement and important role of NO in 
the regulation of hematopoiesis (Krstić et al., 2009, 2010). Spleen is also an active 
hematopoietic organ where response of hematopoietic cells to cytokines depends on the 
tissue microenvironment (Jovčić et al., 2007). Improper signaling inside bone marrow 
stromal cells can lead to their failure and inconsistent microenvironmental niche for 
hematopoietic stem cells. It has been recently shown that basal NO/cGMP/cGMP-
dependent protein kinase (PKG) activity is necessary for preserving bone marrow stromal 
cell survival and promoting cell proliferation and migration (Wong & Fiscus, 2011). Co-
culture studies of human macrophages, as well as human bone marrow endothelial cell line, 
with erythroid progenitor cells resulted in induction of Ǒ-globin mRNA expression in the 
presence of cytostatic hydroxyurea. NOS-dependent stimulation of NO by 
lipopolysaccharide and interferon-Ǒ has been observed in human macrophages. In addition, 
lipopolysaccharide and interferon-Ǒ together increased Ǒ-globin gene expression in human 
macrophage/erythroid cell co-cultures (Čokić et al., 2009). These observations are in accord 
to the intimate contact between erythroid and stromal cells, effects and associations in 
physiological hematopoietic microenvironment. The endothelial cells as well as 
macrophages, normal components of bone marrow stroma, play an active role in the 
modulation of human hematopoietic stem cell growth (Ascensao et al., 1984; Davis et al., 
1005; Hanspal & Hanspal, 2004). The murine endothelial cell lines also stimulate the 
proliferation and differentiation of erythroid precursors, where close cell contact is 
necessary for erythropoiesis (Ohneda & Bautch, 1997). Mice deficient in eNOS, expressed by 
bone marrow stromal cells, demonstrated a defect in progenitor cell mobilization (Aicher et 
al., 2003). Hemoglobin synthesis of erythroleukemia cells line was increased after co-culture 
with endothelial cells and monolayers of bone-marrow-derived macrophages, as well as 
with cell-free culture media conditioned by blood-monocyte-derived macrophages (Zuhrie 
et al., 1988). NO has also an important role in bone marrow angiogenesis, together with 
vascular endothelial growth factor (VEGF), with implications in patients with leukemic 
malignancies (Antic et al., 2010, 2011). NO-cGMP pathway stimulates the proliferation and 
osteoblastic differentiation of primary mouse bone marrow-derived mesenchymal stem cells 
and osteoblasts (Hikiji et al., 1997). NO donors, as well as proteasome inhibitors, inhibited 
cytokine induced intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion 
molecule 1 (VCAM-1) expression (Cobb et al., 1996; De Caterina et al., 1995). The 
proteasome inhibition also significantly enhanced endothelial-dependent vasorelaxation of 
rat aortic rings (Stangl et al., 2004), as well as NO production in endothelial cells (Cokic et 
al., 2007). 
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5. Cyclic nucleotides induction of globin genes expression  
5.1 NO/cGMP stimulation of γ-globin gene expression 
We demonstrated that NO increases Ǒ-globin gene expression in erythroid cells during 
differentiation. Inhibition of soluble guanylate cyclase (sGC) prevents NO-induced increase 
in Ǒ-globin gene expression (Cokic et al., 2003). In addition, we have shown that the well 
known Ǒ-globin gene inducer hydroxyurea stimulated HbF by the NO-dependent activation 
of sGC in human erythroid progenitor cells (Cokic et al., 2003). It has been shown that both 
sGC activators and cGMP induce Ǒ-globin gene expression in human erythroleukemic cell 
line and primary erythroblasts (Ikuta et al., 2001). Therefore, intracellular pathway including 
sGC and PKG induced expression of the Ǒ-globin gene (Ikuta et al., 2001). Moreover, it has 
been reported that hydroxyurea increased NOx levels and NOS-dependent Ǒ-globin 
transcription in erythroleukemic and primary erythroid cells. This Ǒ-globin gene activation 
demonstrated cGMP-dependence (Lou et al., 2009). We found that during human erythroid 
differentiation in vitro, eNOS mRNA and protein levels were initially high but then declined 
steadily, as did the production of NO derivatives, in contrast with steady elevation of 
hemoglobin levels, a potent scavenger of NO (Cokic et al., 2008). According to our previous 
results, hydroxyurea dose- and time-dependently induced rapid but transient activation of 
eNOS in endothelial cells (Cokic et al., 2006). Hydroxyurea stimulated NO production in 
endothelial cells, both as short and long term effects (Cokic et al., 2006, 2007). Chronic 
hydroxyurea therapy significantly increased NO, cGMP, and HbF levels in patients with 
sickle cell anemia (Nahavandi et al., 2002). cGMP levels were found to be significantly 
higher in red blood cells (RBCs) of sickle cell patients than in RBCs of normal individuals, 
and were further increased in RBCs of sickle cell patients on hydroxyurea therapy (Conran 
et al., 2004). NOS activity was also higher in RBCs of sickle cell disease patients on 
hydroxyurea therapy than in untreated patients (Iyamu et al., 2005). It is in accordance with 
results that l-arginine alone does not increase serum NOx production in steady-state 
patients, however it does when given together with hydroxyurea (Morris et al., 2003). 
Neither l-arginine alone nor l-arginine in combination with NOS inhibitor effected 
hydroxyurea-mediated induction of HbF synthesis in erythroid progenitors (Haynes et al., 
2004). L-arginine did not change the suppression of burst forming unit-erythroid (BFU-E) 
colony growth and stimulation of HbF synthesis by hydroxyurea in erythroid progenitors 
(Baliga et al., 2010). Inhibition of NOS attenuated the hydroxyurea and l-arginine effects on 
BFU-E colony growth and HbF synthesis (Baliga et al., 2010), but did not decrease NOx 
production in RBCs during incubation with hydroxyurea (Nahavandi et al., 2006). 
5.2 Nitric oxide synthase levels in red blood cells 
It has been demonstrated that human RBCs contain iNOS and eNOS as well as calmodulin, 
suggesting that RBCs may synthesize its own NO (Jubelin & Gierman, 1996). This notion 
was supported by the observation that RBCs have an active eNOS protein (Chen & Mehta, 
1998). Addition of l-arginine to RBCs stimulated NO production (measured as plasma 
nitrite) in a dose-dependent manner (Nahavandi et al., 2006), whereas it did not significantly 
change NOx levels (Chen & Mehta, 1998). However, it was later reported that RBCs possess 
iNOS and eNOS, but the proteins are without catalytic activity (Kang et al., 2000). Recent 
studies, revealed eNOS protein activity in the cytosol and in the internal side of membrane 
RBCs, serving essential regulatory functions for RBCs deformability and platelet 
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aggregation (Kleinbongard et al., 2006). In vitro NOx production by RBCs (normal and 
sickle) is increased by treatment with hydroxyurea, but it’s not decreased by NOS inhibition 
(Nahavandi et al., 2006). In difference to this result, we showed that hydroxyurea increased 
NO production via induction of eNOS activity in endothelial cells (Cokic et al., 2006). Thus, 
hydroxyurea may increase the plasma concentration of NO by combining endothelial cell 
NOS activity and interaction with oxy/deoxy hemoglobin in RBCs. We found previously 
that hydroxyurea increased cAMP and cGMP levels in human endothelial cells (Cokic et al., 
2006), as well as NO levels via activation of eNOS and proteasome inhibition (Cokic et al., 
2007). Previous reports indicated that cAMP elevation activated the L-arginine/NO system 
and induced vasorelaxation in rabbit femoral artery in vivo and human umbilical vein in 
vitro (Xu et al., 2000). It is known that agents that increase cAMP stimulate eNOS activity in 
human umbilical vein endothelial cells (Ferro et al., 1999). A recent report revealed that a 
rapid increase in endothelial NO production by bradykinin is mediated exclusively by PKA 
signaling pathway (Bae et al., 2003). PKA signaling acts by increasing phosphorylation of 
Ser1177 and dephosphorylation of Thr495 to activate eNOS (Michell et al., 2001). Shear 
stress stimulates phosphorylation of bovine eNOS at the corresponding serine in a PKA-
dependent, but PKB/Akt-independent, manner, whereas NO production is regulated by the 
mechanisms dependent on both PKA and PKB/Akt (Boo et al., 2002). 
5.3 A role of cAMP-dependent pathway in γ-globin gene induction 
During erythroid differentiation adenylate cyclase and cAMP phosphodiesterase activity, as 
well as cellular cAMP concentrations, decline in a synchronized manner (Setchenska et al., 
1981). The cAMP-dependent pathway plays a negative role in a Ǒ-globin gene expression in 
K562 erythroleukemic cell line, in contrast to a cGMP positive role (Inoue et al., 2004). It has 
been also found that, upon activation of the cAMP pathway, expression of the Ǒ-globin gene 
is induced in adult erythroblasts (Kuroyanagi et al., 2006). The subsequent study found that 
the cAMP-dependent pathway efficiently induced Ǒ-globin expression in adult erythroblasts 
of beta-thalassaemia (Bailey et al., 2007). In patients with beta-thalassaemia intermedia, 
cAMP levels were elevated in both RBCs and nucleated erythroblasts but no consistent 
elevation was found with cGMP levels. The transcription factor cAMP response element 
binding protein (CREB) was phosphorylated in nucleated erythroblasts and its 
phosphorylation levels correlated with Ǒ-globin gene expression of the patients (Bailey et al., 
2007). According to previous study, guanylate cyclase inhibition minimally reduced HbF 
induction, whereas adenylate cyclase inhibition markedly decreased HbF induction by 
hydroxyurea in CD34+-derived erythroid cells. Activation of the adenylate cyclase modestly 
induced HbF production, while hydroxyurea failed to significantly stimulate adenylate 
cyclase activity on days 7 to 10 of erythroid cells liquid culture (Keefer et al., 2006). 
However, in our cultures we found that in early erythroid progenitor cell cultures (day 4), 
hydroxyurea stimulated cAMP production (Cokic et al., 2008). It has been also postulated 
that cJun activates the GǑ-globin promoter via an upstream cAMP response element in a way 
equivalent to CREB1 (Kodeboyina et al., 2010). 
5.4 Cyclic nucleotides interaction with phosphodiesterases 
It has been shown that nitrite increased blood flow in the human circulation as well as 
vasodilatation of rat aortic rings. Formation of both NO gas and NO-modified hemoglobin 
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resulted from the nitrite reductase activity of deoxyhemoglobin and deoxygenated 
erythrocytes levels (Cosby et al., 2003). Studies of nitrite activation of sGC demonstrated 
that nitrite alone activated sGC in solution (Jeffers et al., 2005). In our performed in vitro 
studies nitrite failed to induce cGMP, in purified form of sGC in solution, what confirmed a 
major role of NO molecule in hydroxyurea interaction with sGC (Cokic et al., 2008). It has 
been also demonstrated that eNOS is rapidly activated and phosphorylated on both Ser1177 
and Thr495 in the presence of cGMP-dependent protein kinase II and the catalytic subunit of 
PKA in endothelial cells. These processes are more prominent in the presence of 
Ca2+/calmodulin (Butt et al., 2000). The transient rises of cGMP levels induced by 
bradykinin and endothelin-1, which caused release of Ca2+ from internal stores, were 
similarly enhanced by activation of adenylate cyclase and increased cAMP levels. The cAMP 
seems to enhance NO formation, which depends on Ca2+ release from internal stores (Reiser, 
1992). An elevated cGMP level attenuated the store-operated Ca2+ entry in vascular 
endothelial cells (Kwan et al., 2000). The cGMP-mediated [Ca2+]i-reducing mechanisms may 
operate as a negative reaction to protect endothelial cells from the damaging effect of 
excessive [Ca2+]i. The main targets of cGMP are phosphodiesterases (PDEs), resulting in 
interference with the cAMP-signaling pathway (Vaandrager & de Jonge, 1996). cAMP 
hydrolyzing PDE isozymes in endothelial cells are represented by PDE2 and PDE4 as 
cGMP-stimulated and cGMP-insensitive PDE, respectively. In endothelial cells, PDE4 
inhibition may up-regulate basal production of NO, being supported by PDE2 inhibition 
(Lugnier et al., 1999). cGMP-inhibited PDE3 was expressed in K562 erythroleukemic cells at 
a high level (Inoue et al., 2004), while PDE3/4 inhibitor treatment reduced asymmetrical 
dimethylarginine, an endogenous NOS inhibitor, and elevated NO/cGMP levels 
(Pullamsetti et al., 2011). In addition, PDE9A gene expression is increased in CD34+-derived 
erythroid cells and K562 erythroleukemic cells. Inhibition of PDE9A enzyme significantly 
increased production of the Ǒ-globin gene in K562 cells (Almeida et al., 2008). 
6. Nitric oxide-related therapy in hemoglobinopathies 
NO inhibits HbS polymer formation and has anti-sickling properties. NO may disrupt HbS 
polymers by abolishing the excess positive charge of HbS, resulting in increased oxygen 
affinity in patients with sickle cell disease (Ikuta et al., 2011). In sickle cell disease, HbS 
polymerization and intravascular sickling lead to reperfusion injury, hemolysis, decreased 
NO bioavailability and oxidative stress. Increased expression of HbF decreased 
intravascular sickling, accompanied by decreased hemolysis, oxidative stress and increased 
NO metabolites (NOx) levels (Dasgupta et al., 2010). Nitrite can react similarly with adult 
oxy- and deoxy-hemoglobin (HbA), resulting in oxidative denitrosylation of nitrosyl-
hemoglobin and rapid dissociation of NO. RBCs containing oxy-HbF (F-cells) had 
accelerated oxidative denitrosylation. So, induction of HbF present in sickle cell disease may 
enhance vasodilatation in addition to direct inhibition of polymerization of deoxy sickle 
hemoglobin (Salhany, 2008). The role of NO in erythrocyte function, sickle cell anemia, 
malaria, and damage to banked blood has been already reviewed, as well as the use of NO 
targeted therapies for erythrocyte disease (Maley et al., 2010). Pain from vaso-occlusive 
crisis is the major cause of hospitalization in patients with sickle cell disease, where 
beneficial therapeutic effects of inhaled NO have been demonstrated (Head et al., 2010).  
Decreased exhaled nitric oxide levels (FENO) have been described in patients with sickle cell 
disease, together with deficiency in plasma arginine. Additional study shows that sickle cell 
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disease patients, with and without a history of acute chest syndrome, have similar FENO at 
baseline when compared with healthy controls (Sullivan et al., 2010).  
The protecting effects of exogenous NO on murine cerebral malaria are associated with 
decreased brain vascular expression of inflammatory markers, ICAM-1 and P-selectin, 
resulting in attenuated endothelial damage and facilitating blood flow (Zanini et al., 2011). 
Previous reports demonstrated reduced NO levels in severe malaria related to impaired 
production of NO, reduced mononuclear cell iNOS expression and NOS substrate arginine 
(Anstey et al., 1996; Lopansri et al., 2003). Responsible factors for low NO levels in malaria 
include scavenging of NO by free hemoglobin and superoxide anion, and reduced levels of 
nitrate, a NO precursor molecule (Lopansri et al., 2003). Endothelial activation plays a 
central role in the pathogenesis of severe malaria with angiopoietin-2 as a key regulator. NO 
is a major inhibitor of angiopoietin-2 release from endothelium and has been shown to 
decrease endothelial inflammation and reduce the adhesion of parasitized RBCs. Low-flow 
inhaled NO is an attractive new candidate for the adjunctive treatment of severe malaria 
(Hawkes et al., 2011). Exhaled NO was also lower in severe malaria in comparison to 
moderately severe falciparum malaria and controls. Intravenous administration of l-arginine 
increased exhaled NO in moderately severe malaria (Yeo et al., 2007). 
7. Conclusion: Nitric oxide and soluble guanylate cyclase 
Besides direct stimulation of sGC in erythroid cells, NO is produced by stromal cells of bone 
marrow hematopoietic microenvironment. NOS enzymes in stromal cells are activated via 
PKA, supported by intracellular Ca2+ elevation. NO has been released into the intercellular 
space and then passed through the plasma membrane of erythroid cells, where it binds 
directly to ferrous-deoxy heme of sGC, activating the enzyme. Activation of NO-sGC 
increases conversion of GTP to cGMP, resulting in elevation of cGMP and subsequent 
activation of cGMP-dependent protein kinases (PKG) and cGMP-hydrolyzing PDEs. 
Activation of sGC and PKG increases expression of the Ǒ-globin gene in erythroid cells. NO 
reduces cAMP levels in erythroid cells, whereas cAMP appears to enhance NO formation. 
The NO-mediated cAMP-reducing mechanisms may operate as a negative feedback in 
control of cAMP levels. In addition, cGMP enhances cAMP level and cAMP-signalling 
pathway by competing for the PDEs active site that has modest cyclic nucleotides selectivity 
(e.g., PDE3 isozymes). By this way, cGMP inhibits the activity of cAMP-specific PDE3, 
which results in the increase in intracellular cAMP levels and thereby leads to the activation 
of PKA. Activation of the cAMP-dependent pathway also induces expression of the Ǒ-globin 
gene in erythroblasts. The phosphorylation levels of CREB correlated with elevated Ǒ-globin 
gene expression. Moreover, inhibition of PDE9A enzyme significantly increases production 
of the Ǒ-globin gene. Therefore, it appears that activation of the linked cGMP- and cAMP-
signalling pathways regulates Ǒ-globin expression. 
Presented results contribute to the understanding of the significance of NO participation in 
Ǒ-globin induction. These results should support future studies, with the emphasis focused 
on the hematopoietic microenvironment, in search of therapy of sickle cell disease. In 
addition to the possibility of NOS presence and activity in mature RBCs, our data show 
strong eNOS protein levels and function in more primitive human erythroid progenitor and 
precursor cells, where control of gene expression occurs. While mechanisms involved in 
globin gene expression have been recognized at different levels within the regulatory 
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hierarchy, relations between molecular pathways are only emerging. Our presented 
microarray results demonstrated the broad gene expression profile and related pathways 
linked to stimulation of globin genes during ontogeny. The presented genes and signaling 
pathways, involved in the mechanism of globin genes activation, might be targets for 
therapeutic agents that upregulate Ǒ-globin gene expression and HbF levels in 
hemoglobinopathies. This ontogenic overview linked to specific genes and transcriptional 
programs in normal erythropoiesis may contribute to further understanding of erythroid 
progenitor cell development.  
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